First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantationRizwan Romee, Jeffrey S. Miller, Celalettin Üstün et al.|Blood|2018Cited by 406
CD56bright NK cells exhibit potent antitumor responses following IL-15 primingJulia Wagner, Todd A. Fehniger, Maximillian Rosario et al.|Journal of Clinical Investigation|2017Cited by 311
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell LymphomasMaximillian Rosario, Todd A. Fehniger, Bai Liu et al.|Clinical Cancer Research|2015Cited by 147
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor ResponsesBai Liu, Hing C. Wong|Journal of Biological Chemistry|2016Cited by 79